RxDoctor Payments Data

Jonathan Pasko, MD

Internal Medicine · Monroe, MINPI 1962452904

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 46 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$176
  • Novartis$117
  • Novo Nordisk$91
  • GSK$82
  • Pfizer$77
  • Hologic Sales And Service, LLC$75
  • plus $442 from 14 others

What the payments were for

  • Food & beverage$1,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$82,632
Medicare patients
182
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$59,511
TrulicityDulaglutide30$52,304
EliquisApixaban39$40,129
JardianceEmpagliflozin31$38,991
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$29,345
MounjaroTirzepatide14$19,143
MyrbetriqMirabegron17$15,724
JanuviaSitagliptin Phosphate11$12,592
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$10,902
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$10,378
EntrestoSacubitril/Valsartan12$7,807
Fentanyl33$4,540
VyvanseLisdexamfetamine Dimesylate11$4,102
Gabapentin84$2,537
Atorvastatin Calcium164$2,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$70$71,44744 claims
Novo NordiskOzempic$91$59,51137 claims
PfizerEliquis$77$40,12939 claims
Boehringer IngelheimJardiance$14$38,99131 claims
GSKTrelegy Ellipta$82$29,34517 claims
MerckJanuvia$35$12,59211 claims
NovartisEntresto$117$7,80712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →